Affinity 2007 Conference
NYU Kimmel Center, New York, NY
July 8 - 12, 2007
Program and Speaker Biographies (as of June 30, 2007)
Sunday, July 8, 2007 |
|
Introduction |
George Ehrlich, Hoffmann - La Roche, Nutley, NJ |
Keynote Lecture |
A Human Protein Atlas Based on Affinity Proteomics |
|
|
Opening Ceremonies |
Richard Willson, |
Chairman Introduction |
Session 1: Affinity: Past, Present and Future |
101 |
My Life with Affinity: Essentials of Biorecognition and its Application |
102 |
Monolith Supports with Affinity and Pseudo Affinity Ligands for Superfast Purification of Biomolecules |
|
Coffee/Posters/Exhibits |
103 |
Immunodepletion - What's Beneath the Tip of the Plasma Proteome Iceberg? |
104 |
The NCI’s Clinical Proteomic Technology Initiative for Cancer - The Reagent Resource Core |
Lunch/Workshop |
Flexible Formats for Characterizing and Screening Protein-Protein Interactions using Bio Layer Interferometry on the Octet System
Matthew Kirtley ForteBio, Inc. |
Chairman Introduction |
Session 2: Advances in Affinity Technologies |
201 |
Evolution of Industrial Affinity in Biopharmaceutical Production |
202 |
Efficiency Improvements in the Discovery and Development of Novel Antibody Format and Protein-Based Biotherapeutics Using CaptureSelect® Affinity Ligands and Yeast Display Discovery Tools |
|
Coffee/Posters/Exhibits |
203 |
Generation of Fully Human Antibodies Derived from Fab-on-phage Display Libraries. Rapid Kinetic-based Screening of Fab Fragments for Lead Identification |
204 |
Novel Approaches to Affinity Screening |
|
Roche Younger Investigators 4:35 - 4:50 4:50 - 5:05 5:05 - 5:20 5:20 - 5:40 5:40 - 6:00 |
|
ISMR Council Meeting/Posters/Exhibits |
|
|
Chairman Introduction |
Session 3: New Developments in Chromatography |
301 |
Mathematical Modeling of Elution Curves for a Protein Mixture in Chromatography Applied to the Optimal Selection of Operating Conditions |
302 |
Affinity Interaction under Chaotropic Conditions |
|
Coffee/Posters/Exhibits |
303 |
ImmunoAffinity Capillary Electrophoresis for the Identification and Characterization of Toxic Biomarkers |
304 |
Biacore Applications for Effective Bio-therapeutic Development |
Lunch/Workshop |
Success Story of MabSelect |
|
Please stand by your poster/exhibit |
Chairman Introduction |
Session 4: Nano/Bio/Materials |
Pierce Award Lecture |
Molecular Recognition of Proteins on Surfaces and the Development of Critical Hydrophobicity HIC |
401 |
Analyte-Responsive Retro-reflectors for Biochemical Assays and Diagnostics |
|
Coffee/Posters/Exhibits |
402 |
Gold Nanorod Substrates for Localized Surface Plasmon Resonance Sensing |
403 |
Discovery and Development of OMNiMIPs: One MoNomer Molecularly Imprinted Polymers |
Panel Discussion |
Trends in Label-free Interaction Analysis |
|
Posters/Exhibits/Dinner on your own |
|
|
Chairman Introduction |
Session 5: Insights into Intra- and Inter- Molecular Recognition |
501 |
Self-Assembly of Soft Molecular Networks: Crystal Design and Curvature |
502 |
Molecular Recognition of Foreign Sequences in Engineered 5S Ribosomal RNA |
|
Coffee/Posters/Exhibits |
503 |
Small-molecule-mediated Rescue of Protein Function by an Inducible Proteolytic Shunt |
Social Event |
Walking Tour of the Village featuring Arthur Marks |
Chairman Introduction |
Session 6: Protein Interactions In and On Cells |
601 |
Dynamic Visualization of Signaling Activities in Living Cells |
602 |
Structure and Function of Eukaryotic RNA Exosomes |
|
Coffee/Posters/Exhibits |
603 |
Electrophoretic Fingerprinting of HIV-1 Cell Interaction: a Novel Tool for Development of Charge-Based Strategies |
|
Irwin Chaiken,
|
|
Please stand by your poster/exhibit |
|
Gala Dinner Cruise on |
|
|
Chairman Introduction |
Session 7: Viruses and Vaccines |
701 |
Ligand Recognition and Plasticity in HIV Envelope Glycoprotein gp120 |
702 |
The Role of Antibodies in Preventing and Treating HIV Infection |
|
Coffee/Posters/Exhibits |
703 |
Biomolecule Recognition in Piezoelectric Immunosensors: Application of Piezoimmunosensors for Detection of HIV1 Virion Infectivity Factor |
704 |
Interaction of gp340, a Glycoprotein in the Innate Immune System, with HIV-1 env |
ISMR General Meeting |
Presidential Announcements |
Lunch Break |
Posters/Exhibits/Lunch on your own |
Chairman Introduction |
Session 8: Drug Discovery and Diagnostics |
801 |
The Economics of Personalized Medicine: Optimizing Incentives for Innovation |
802 |
Biomimetic and Supramolecular Scaffolds for Multivalent Display |
803 |
Designing for Success: The Generation of Useful Leads with Small Molecule Libraries |
804 |
Cancer Chemotherapy with an FDA Approved |
|
Affinity 2009: the 18th Biennial Meeting of the International Society for Molecular Recognition |
Speaker Biographies
Mathias Uhlén
Mathias Uhlén is Professor of Microbiology at the Royal Institute of Technology (KTH), Stockholm, Sweden. Dr Uhlén is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA) and the European Molecular Biology Organization (EMBO). He is Vice-President of the European Proteomics Association (EuPA) and member of the Human Proteome Organization (HUPO) council. He was Vice-President of the Royal Institute of Technology (KTH), responsible for external relations, from 1999 to 2001 and he was the chairman of the Swedish Biochemical and Molecular Biology Society (SFMB) from 1994 to 1999. Dr Uhlén has more than 280 publications in bioscience with the focus on the development and use of affinity reagents in biotechnology and biomedicine.
In the early eighties, Dr Uhlén cloned and characterized staphylococcal protein A, which is now used extensively for purification of antibodies both in diagnostics and therapy. He showed in 1983, for the first time, the principle of affinity capture of fusion proteins. The use of affinity tags for purification of recombinant proteins are now widely used in bioscience. In the late eighties, Uhlén published the use of magnetic micro spheres with streptavidin for automated solid phase applications. Such laboratory systems based on streptavidin beads are at present frequently used both in research and diagnostics. In the 90’ies, his group described a new principle for affinity reagents, called Affibodies, and showed their use as research tool and recently as potential cancer therapeutics. Uhlen and colleagues also developed a new strategy for DNA analysis called Pyrosequencing, a method that has recently been further developed by a US company (454) into a highly parallelized sequencing instrument.
Dr Uhlén is currently working on the Human Protein Atlas (HPA) program, with the aim to systematically map the human proteome. In October 2006, version 2.0 of the Protein Atlas was published (www.proteinatlas.org) with more than 1.2 million high-resolution images representing 1,359 human proteins. He has founded several companies, including Pyrosequencing AB (Biotage AB), Affibody AB, SweTreeGenomics AB, Magnetic Biosolutions AB, Creative Peptides AB and Atlas Antibodies AB. He has received numerous awards, including The Svedberg prize in 1992, the Göran Gustavsson prize in 1993, the gold medal of the Royal Swedish Academy of Engineering Sciences in 2004, the Most Noble Order of the Seraphim - the Order of His Majesty the King in 2004, the Jerker Porath award and the Akzo Nobel Award in 2005 and the HUPO Distinguished Achievement Award in 2006.
Meir Wilchek
Professor Meir Wilchek has always worked in the interface between organic chemistry and biology, played a pivotal role in the use of the principles of organic chemistry (known today and chemical genetics) for the understanding of biological processes and the establishment of the modern-day concept of biorecognition and its development for the myriads of applications in the various fields of modern biology. This concept and the associated processes, which Meir Wilchek has designed, have had a profound effect on research, industry, medicine, molecular biology, and, consequently, on the human condition in general. In view of the inherent clinical and medical implications of Dr. Wilchek's discoveries, it should come as no surprise that among the list of prizes he has already received, which include the prestigious Wolf Prize, the Israel Prize, and the Pierce Prize, he was elected to the Institute of Medicine of the National Academy of Science, USA.
Meir Wilchek's studies have been directed towards the understanding and application of the biorecognition phenomenon using chemical methods, and his major contributions have been directed in four different but related aspects: namely, affinity chromatography, affinity labeling, affinity therapy and avidin-biotin technology. Historically, the contribution for which he is best known and for which he has received the most internationally acclaimed awards and honors is the field of affinity chromatography and the avidin-biotin system. In addition, his contributions to the other above-mentioned fields have been of critical scientific impact. In all the above fields, in which he was among the founders, he had to device chemical methods to immobilize, derivatize biological active molecules, such as protein, nucleic acid and even whole cells. All these methods are widely used all over the world.
Adam Michael Clark
Dr. Clark has a background in both medical science research and health policy. Dr. Clark has served as both a researcher and a program administrator for the National Cancer Institute. In addition to his work with the CPTI, Dr. Clark served as the Life Science Policy Analyst at the White House's Office of Science and Technology Policy working on a variety of issues including overweight/obesity health issues and strategies, stem cell research, and cancer imaging technologies. Dr. Clark also served as the science policy advisor for the Deputy Chief of Staff in the Office of the Secretary, Department of Health and Human Services working on several key projects in the Department including the 2005 Dietary Guidelines for Americans. Dr. Clark returned to the NCI Office of Technology and Industrial Relations in 2005.
Dr. Clark has a Ph.D. in Environmental Health from the University of Cincinnati College of Medicine with an emphasis on gene-environment interactions in disease onset and targeted treatment. Dr. Clark's research experience focused on alterations of signal transduction pathways in tumorigenesis. He was enrolled in the Graduate Partnership Program at the National Institutes of Health and was a 2002 recipient of the Cancer Research Training Award from the National Cancer Institute where he completed his graduate studies and postdoctoral work.
Lars Hagel
Lars Hagel is Director of External R&D Collaborations at GE Healthcare Bio-Sciences AB,
Duncan Low
Duncan Low, Scientific Executive Director, joined the Process Development Department at Amgen in 2003, where he leads cross-functional teams for technology evaluation, technology development and Process Analytical Technology. He is a member of the ISPE Executive Committee for PAT and chairs the ASTM E55.01 subcommittee. Prior to joining Amgen he held senior positions at Millipore and Pharmacia Biotech. He has extensive experience of the tools currently in use in upstream and downstream processing and has worked closely with applications development throughout the industry. He has an M.A. in biochemistry from the University of Cambridge and a Ph.D. in microbiology from the University of Glasgow.
Hendrik Adams
Prior to joining The Bio Affinity Company (BAC) as Ligand Discovery Scientist, Hendrik Adams was a postdoctoral scientist in the Cellular Architecture & Dynamics group of Utrecht University (The Netherlands). In this group, he carried out research for the application of llama antibodies in medical devices. Previously, he was a postdoctoral scientist within a Marie Curie Research Training Network funded by the European Union. In that position, he studied the iron uptake in the opportunistic pathogen Pseudomonas aeruginosa in the department of Receptors and Membrane Proteins at the University of Strasbourg (France). He received his Ph.D. degree in the field of Molecular Microbiology from the Utrecht University.
Mark S. Baker
Received his BSc Hons 1 in 1981 & PhD in 1985Macquarie University and undertook postdoctoral studies at Monash University, John Curtin School of Medical Research and Howard Hughes Medical Research Institute University of Michigan. Mark is currently the Chief Executive Officer of a Major National Research Facility called the “Australian Proteome Analysis Facility” and he is also Professor of Proteomics, Dept. Chemistry & Biomolecular Sciences, Macquarie University.
Mark’s previous industry experience is in the development of new biochip platforms (through LumiCyte California, USA). He was the founder of the Gynaecological Cancer Research Centre, Royal Women’s Hospital, Melbourne, is a Council Member of HUPO and Asia Oceania HUPO as well as Secretary of the Australasian Proteomics Society. Mark is currently a member of the Science Industry Action Agenda Leader’s Group. He won the 1994 Sports Medicine Australia Order of Fellows, the 1991 Howard Florey Young Investigator Medal and the 1988 & 1990 International Young Investigator Awards from the Society for Free Radical Research. He has over 80 publications, 3 patents, has trained ~20 PhD students and ~30 BSc(Hons)/BBiotech students.
Mark’s interests are in biomarker discovery, proteomic technologies, research commercialisation, building the Australian biotech sector and Rugby. He holds grants with proteomics industry leaders (eg. GE Healthcare, QIAGEN, Applied Biosystems) and has most recently developed novel immunodepletion strategies using chicken eggs.
Enrique Carredano
Dr. Enrique Carredano holds a Degree of Doctor of Technology from the Swedish University of Agricultural Sciences in the area of Structural Molecular Biology (x-ray protein crystallography). From June 1999 he has been working as a scientist at GE Healthcare Biosciences AB in Uppsala, contributing to research and development projects with molecular modeling expertise within the area of modeling affinity and ion-exchange interactions for chromatography. His most recent area of focus has been in the implementation of robot applications for high throughput screening of chromatographic parameters for process development.
Juan Asenjo
Juan A. Asenjo de Leuze is a chemical engineer from the University of Chile and he obtained his PhD from University College London in 1978. He obtained the National Science Prize in 2004. His research work in the Biotechnology field is shown by 160 international scientific publications, 4 international patents and 4 books edited. He has supervised a large number of PhD students (41) in the USA, England and Chile and has had 11 postdoctoral fellows. He was Associate Professor and Director of the Biochemical Engineering Laboratory at Columbia University (New York, 1980-1986) and created such a laboratory in the University of Reading (Reader) in England (1986-1994). He is a member of the Editorial Committee of 6 international scientific journals in biotechnology and bioengineering, Vice President of the Chilean Academy of Sciences (and Foreign Officer) and the only engineer ever to obtain a Presidential Chair in Sciences (1997).
Rainer Hahn
Rainer Hahn received a Ph.D. in Biotechnology at the Department of Biotechnology at the
A. Cecilia Roque
Cecília Roque is an Assistant Professor and Researcher at the Faculty of Sciences and Technology in Lisbon. Cecília obtained a degree in Chemical Engineering (Biotechnology specialization) in 1999 and a PhD in Biotechnology in 2004 by Instituto Superior Técnico ( Portugal) in collaboration with the University of Cambridge (UK). She has been a visiting scholar, supervisor of students and a post-doc researcher at the Institute of Biotechnology, University of Cambridge (UK) between 1999 and 2005.
Fredrik Sundberg
As Director of Market Development for the pharmaceutical and biotech industrial sector, Mr. Sundberg is responsible for expanding the application of label free interaction analysis throughout drug discovery and development, in-process and quality control workflows. He advises on in-house development projects and has specialist knowledge in the area of validation support and frequently provides GxP (GLP, GCP, GMP) training to the pharmaceutical industry. He has conducted several pharmaceutical development projects, completed validation studies for a variety of analytical instruments and process equipment, and produced more than 100 IQ/OQ/PQs for different pharmaceutical companies worldwide. Mr. Sundberg is the author of several publications and articles in the field of using biosensor technology for productivity improvements and GxP quality control. During the past several years, Fredrik has presented at numerous premier conferences globally. On a regular basis, he lectures and discusses regulatory issues with organizations from both industrial and government authorities and advises on in-house development projects.
Paul Ruchhoeft
Dr. Paul Ruchhoeft is an Assistant Professor of Electrical and Computer Engineering at the University of Houston and is the author of over 20 archival publications ranging from the fundamentals to applications of nanolithography. His research interests include micro-and nano-fabrication using ion beam proximity lithography, thin-film deposition and etching, development of retroreflector-based diagnostic tools, and the modeling of resist exposure and development.
Jason Hafner
Jason H. Hafner received his B.S. degree in Physics from
David Spivak
David Spivak received his B.S. degree in Chemistry from UC Berkeley in 1989, and his Ph.D. degree in Polymer/Organic Chemistry from UC Irvine in 1995, under the direction of Professor Ken Shea. He then was awarded an NIH Post-Doctoral Fellowship for his proposal to study catalytic antibodies for polymerization and other reactions at The Scripps Research Institute from 1995 to 1998. Afterward he began his professional career at Louisiana State University (LSU) in Baton Rouge, where he presently resides as an Associate Professor of Chemistry. Research in the Spivak Group is multidisciplinary, focused on Molecularly Imprinted materials, thin films and nanoparticles for biological and environmental analysis. In addition to research funding from NIH and NSF, including an NSF-CAREER award, Professor Spivak has received teaching awards from Research Corporation (Cottrell Scholar), and LSU (The LSU Athletic Foundation Undergraduate Teaching Award for 2001). He is also an Associate Editor for the Journal of Molecular Recognition.
Michael Ward
Professor Ward attended William Paterson College and graduated in 1977 with a Bachelor of Arts degree in Chemistry. He received a Ph.D. in Chemistry from Princeton University in 1981. His thesis research, under the mentorship of Professor Jeffrey Schwartz, was on the "Investigation of Oxide Bound Transition Metal Complexes." Upon his graduation, he worked as a Robert A. Welch Postdoctoral Fellow with Professor Allen J. Bard at the University of Texas (Austin) to investigate the fundamentals of semiconductor particles.
From 1982 to 1984, Mike was a Project Leader at the Standard Oil Company of Ohio. From there, he moved on to work in Central R&D at E.I. duPont de Nemours and Co as a Research Scientist. In 1990 he joined the faculty at the University of Minnesota, where he held the positions of Distinguished McKnight University Professor and Director of the NSF-funded Materials Research Science and Engineering Center in the Department of Chemical Engineering and Materials Science.
In 2006, he assumed his current position at New York University as Director of the Molecular Design Institute and Professor of Chemistry, where he continues as an Editor of the ACS journal, Chemistry of Materials. One of his principal research interests is in the area of the design, synthesis and crystal growth of crystalline molecular solids in which the molecules are held together in a lattice by weak, and often unpredictable, intermolecular interactions.
M.A. Vijayalakshmi
Viji is Professor in the Department of Bioengineering and Director of the Molecular Interaction and Separation Technology Laboratories at the Université de Technologie de Compiègne. She is also Director of the Centre for BioSeparation Technology at the Vellore Insitute of Technology at
Viji received her Doctorat D'Etat es Science (D. SC) on the topic of Affinity Chromotography And Molecular Interactions in June 1980 from the Universite De Technologie de Compiegne, France. She received her M.Sc. in March 1966 from All India Institute of Chemistry in
She became Distinguished Professor at Universite de Technologie de
She was appointed as Member of the "Standing Advisory Council-Overseas" to the Secretary of State in the Ministry of Science and
In July 1999, she was awarded the Prestigious Pierce Award for the outstanding achievements in the field of Affinity Technology and Bio Recognition at the International level.
She was conferred the Title of "CHEVALIER de Honor des Palmes Academiques" by the French Republic President Jacques Chirac, in Oct. 2004
She holds more than 120 publications and 6 patents to her credit, all dealing with pseudo bio specific affinity systems.
About 90 persons from 36 different countries have thus benefited from this type of training in her lab, for periods varying from one month to five years. Under différent exchange programmes, she sends her pupils regularly to many different labs at the international level for short term trainings.
At present she has 20 scientists working in her new Indo-French Excellency Centre in
In addition she has served NSF, EU and other international organisations as expert. Her links with industries and academia worldwide make her a good science ambassador.
Marc Vanhove
Marc Vanhove holds a PhD in Biochemistry (1995) from the University of Liège (Belgium). His doctoral studies aimed at a better understanding of the mechanisms by which b-lactamases fold, i.e. acquire their native, three-dimensional structure. After a short stay at the University of Bayreuth (Germany) where he investigated the early steps of the refolding of his favorite enzymes, Marc received a post-doctoral appointment at the Department of Tumor Cell Biology at St Jude Children’s Research Hospital (Memphis, TN, USA) in 1999 as a fellow of the F.N.R.S., then joined Dyax in 2001 and is now Associate Director of Research.
Matthew Pratt
Matthew Pratt received his BS in biochemistry and mathematics from
Irwin Chaiken
Dr. Chaiken attended Brown University and graduated in 1964 with a Bachelor of Arts degree in Chemistry and a minor in Biology. He received a Ph.D. in Biological Chemistry from University of California at Los Angeles in 1968.
His thesis research, under the mentorship of Prof. Emil Smith, was on "Studies of the Catalytic Center of Papain". He worked as an NIH Postdoctoral Fellow with Dr. Christian Anfinsen on the use of chemical semisynthesis to study structure-function relationships in staphylococcal nuclease. In 1970, he joined the staff of NIH, first as a Staff Fellow and, starting in 1973, as a Senior Investigator. In 1988, he moved to SmithKline Beecham, where he served as director of the Macromolecular Sciences Department and then as a Research Fellow in the Molecular Immunology Department of Biopharmaceuticals Research. In 1995, he moved to University of Pennsylvania, where he became Research Professor of Medicine. He assumed his current position as Professor of Biochemistry and Molecular Biology at Drexel University College of Medicine in February 2003.
Dr. Chaiken's research has been centered in the area of molecular and structural mechanisms of protein recognition and antagonism. His current research projects are focused on receptor interaction mechanisms, including for cytokine receptors in inflammation and HIV-1 envelope complexes in host cell entry; molecular mimicry using protein and miniprotein scaffolds, including design, synthesis and receptor of antagonists for disease treatments; and elucidating molecular recognition mechanisms using biosensors, including development and application of methods for nano and cell sensing studies.
Jin Zheng
Dr. Zhang received her doctoral degree in chemistry from the
Current topics of interest in her lab at Johns Hopkins include: investigating the spatiotemporal regulation or dysregulation of protein kinases (PKA, Akt/PKB and AMPK) and second messengers in cell migration, energy metabolism and cancer development; developing new technology for multi-dimensional kinase profiling; designing and synthesizing molecular tools for monitoring and perturbing second messenger dynamics in live cells; mechanistic computational modeling and systems analyses of signaling networks; and developing live-cell high-throughput screening methods for identifying kinase regulators.
Christopher D. Lima
Christopher D. Lima received his PhD from Northwestern University in 1994 for work on the structure determination and characterization of E. coli Topoisomerase I, work was completed in the laboratory of Dr. Alfonso Mondragon in collaboration with Dr. James Wang. In 1995, Dr. Lima joined the laboratory of Dr. Wayne A. Hendrickson as a Helen Hay Whitney Fellow where he characterized the biochemical and structural basis for HIT nucleotidyl transferase family, members of which include aprataxin and FHIT. In the fall of 1998, Dr. Lima joined the faculty at the Weill Medical College of Cornell University as an Assistant Professor. In 2002 he was promoted to Associate Professor and in 2003, Dr. Lima moved his laboratory to the Sloan-Kettering Institute where he is now an Associate Member within the Structural Biology Program. During this period, Dr. Lima has received the Louise and Allston Boyer Young Investigator Award, Mayor's Award for Excellence in Science and Technology, Beckman Young Investigator Award, Dorothy Rodbell Cohen Foundation Award for Sarcoma Research. He was also named a Rita Allen Scholar. Since starting his lab, Dr. Lima’s research has focused in two principle areas of biology, post-translation protein modification by the ubiquitin-like modifier SUMO, and on RNA processing, 5’ cap formation, and RNA decay.
David Fairhurst
Dr. David Fairhurst is a consulting advisor on microbicide formulations (semisolids, films, tablets, rings) to the International Partnership for Microbicides.
Dr. Fairhurst was, formerly, Executive Vice President/Chief Technology Officer with Particle Sciences/ NPR Healthcare Inc. Particle Sciences is a CRO that specializes in controlled drug delivery. NPR manufactures skin-care products targeted specifically for dermatologists, plastic surgeons and aestheticians. He headed the team that invented some of today’s most innovative ingredients for sunprotection, including Z-COTEÔ a transparent zinc oxide voted by Forbes magazine as one of the top ten nanotechnology products in 2003 and SunCapsÔ (encapsulated actives). Dr. Fairhurst was directly involved in discussions with the FDA to have zinc oxide included in the Final Monograph on Sunscreens, and labeled as a Category I sunscreen active. He has been personally involved in the formulation of hundreds of skin, diaper, eye and lip products.
Dr. Fairhurst received his Ph.D. in Physical Chemistry in 1968 from Liverpool Polytechnic,
Dr Fairhurst has over 40 years experience in the practical application of colloid and surface chemistry and dispersion/emulsion technology. He has authored 25 Confidential Business Reports and Classified Government Documents, is entitled to four patents and has published 100 technical papers, scientific articles and book chapters in the open literature. David is a member of various professional societies in both the
Wayne Hendrickson